Objective:

To highlight recently published research by Dana-Farber faculty, specifically those listed as first or senior authors, from November 16 - 30, 2025.

Key Findings:

• HLH is a life-threatening condition requiring early recognition and intervention to prevent irreversible damage.
• PTEN loss leads to a druggable mechanism involving p-PI3K?Y962, promoting tumorigenesis and offering new therapeutic avenues.
• BCL-w dimer inhibits BAX oligomerization, affecting apoptosis induction, which may inform future cancer therapies.
• Eltrombopag shows a significantly higher sustained platelet response in pediatric patients compared to standard therapy, indicating its potential as a first-line treatment.

Interpretation:

The findings underscore the importance of targeted therapies in managing complex hematologic and oncologic conditions.

Limitations:

• The review does not cover primary HLH, which is addressed in a separate article, limiting the scope of understanding secondary HLH.
• The clinical trial results may be limited by sample size and specific patient demographics, which could affect generalizability.

Conclusion:

Recent research highlights advancements in understanding and treating critical hematologic disorders and cancer, emphasizing the need for targeted therapies and the potential for improved patient outcomes.